Oxford Nanopore Technolo... Share Discussion Threads

[bamboo2] 08/10/2024 07:08

08/10/24

Great article about Plasmids.

The unreasonable effectiveness of plasmid sequencing as a service (Plasmidsaurus)

[bamboo2] 08/10/2024 07:06

8 October 2024

Oxford Nanopore Technologies plc

Notification of intention to transfer listing category

Oxford Nanopore Technologies plc ("Oxford Nanopore" or the "Company"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces that it is proposing to transfer the listing category of its ordinary shares (the "Ordinary Shares") from the equity shares (transition) ("Transition") category to the equity shares (commercial companies) ("ESCC") category on the official list ("Official List") of the Financial Conduct Authority ("FCA") under Rule 21.5 of the UK Listing Rules ("UKLR") as modified by Transitional Provision 2 (the "Transfer").

The provision of a minimum of 20 business days' notice (which period commenced by way of today's announcement) is required to effect the Transfer. It is anticipated that the Transfer will take effect at 8:00 a.m. GMT on 6 November 2024.

No shareholder approval is required in connection with the Transfer.

This announcement is being made in accordance with UKLR 21.5.7.

Dr. Gordon Sanghera, Chief of Executive Officer of Oxford Nanopore, commented:

"We are proud of all we have achieved since our IPO in 2021, including significantly growing our revenues, customer base and impact in the scientific community. Today we are more excited than ever about the opportunities for our unique platform, that provides richer, multi-omic data, faster and more accessibly and affordably. As we look ahead, now is the right time for Oxford Nanopore to transfer to the ESCC segment. We believe it will provide exposure to a wider investor base and eligibility for FTSE index inclusion, enhancing the liquidity of our shares, for the benefit of our shareholders"

[bamboo2] 04/10/2024 08:14

Anti-takeover shares expiring tomorrow means that from next Monday ONT becomes a potential target for acquisition. ONT spans the space between the tech and medicine so there are numerous possible suitors around the world, many with huge amounts of cash at their disposal.

There have been some large blocks of stock sold over the past few years and in many cases we have no idea on the identity of the buyer. Shorters have had three years to make hay free from concerns about possible corporate activity.

From Monday the stock becomes legible for inclusion in the indices, so will start to find it's way into trackers, and funds that previously excluded this type of share.

The anti-takeover shares were an attempt to prevent ONT tech going the same way as the SBS [Solexa] tech that powers Illumina sequencing. Hopefully we will now see the brakes come off the price.

[shared24] 03/10/2024 21:08

Any guesses on how the last day of trading tomorrow will end before take-over clause expires?

[p1nkfish] 01/10/2024 06:30

Makes a lot of sense, a good addition.

[bamboo2] 01/10/2024 06:07

Novo NED joins board.

1 October 2024



Oxford Nanopore Technologies plc

Dr Daniel Mahony appointed as Non-Executive Director



Oxford Nanopore Technologies plc (LSE: ONT) (''Oxford Nanopore'' or ''the Group''), the company delivering a new generation of nanopore-based molecular sensing technology, is pleased to announce that Dr Daniel Mahony will be joining the Group as a Non-Executive Director with effect from 1 October 2024.

Daniel brings extensive sector experience to help accelerate Oxford Nanopore's commercial traction, with more than 25 years as a global healthcare investor specialising in biotechnology, medical technology and healthcare services. As Senior Partner in Growth Investments at Novo Holdings, Daniel will serve as a critical sounding board to the Group as it continues to advance its technology platform to address a significant commercial opportunity in biopharmaceuticals. In addition, he currently chairs the UK BioIndustry Association and is a Non-Executive Director of the Wellcome Sanger Institute.

Prior to joining Novo Holdings, Daniel co-founded the healthcare business unit at Polar Capital in London, growing it to more than $4 billion in assets under management. He was formerly a Senior Research Analyst at Morgan Stanley in London, an Analyst at ING Barings Furman Selz in New York, and completed his postdoctoral work at DNAX Research Institute in Palo Alto.

Dr Guy Harmelin, a non-executive director of the Group, who has served on the Board since 2020, has informed the Board of his intention to step down from the Board with effect from today. Dr Guy Harmelin, is stepping down to focus on various other Directorship responsibilities.

Duncan Tatton-Brown, Chair of Oxford Nanopore, said: "We are extremely pleased to welcome Daniel to the board as Non-Executive Director of Oxford Nanopore. Daniel's deep knowledge of the biopharma sector, combined with his understanding of Oxford Nanopore's opportunity to drive value across the biopharma development pipeline, position him as an ideal source of expertise to support the company's commercial expansion into this space. I would like to thank Guy, our outgoing non-executive director for his outstanding support overall and contribution in helping the Group transition from a private to a public company during his tenure."

Dr Daniel Mahony, incoming Non-Executive Director of Oxford Nanopore, said: "This is an exciting time for Oxford Nanopore with its expanding opportunity in biopharma, where rapid sequencing, richer data and a streamlined platform can support discovery and delivery of new biopharmaceuticals. I look forward to bringing my industry expertise to bear as Oxford Nanopore executes against its exciting growth plans in this sector."

Dr Gordon Sanghera, Chief Executive Officer of Oxford Nanopore, said: "Daniel brings substantial strategic experience to support Oxford Nanopore's commercial growth in the life sciences and specifically the biopharma market. His perspectives will be invaluable as we continue to expand the use of our technology to address the needs of this industry, and I look forward to working with Daniel as we enter this next phase. I also would like to thank Guy, our outgoing non-executive director, for his insight and guidance during his tenure on the board. We appreciate his significant contribution and wish him well in his next chapter."

Novo Holdings is a shareholder in Oxford Nanopore and led the recent £80 million equity placing. The decision to appoint Dr Mahony to the Board of Oxford Nanopore reflects his considerable industry expertise and the value he brings to the Board.

[bamboo2] 30/9/2024 21:20

Schroders Capital Global Innovation Trust Plc [catchy!] updated this morning...

...ONT holding valued at 30/6/24 £10,173,000/.944p [closing share price on Fri 28/6/24] = 10,776,483 shares

As at 30/6/24 INOV, AKA Nortrust, formerly SUPP, formerly Woodford Patient Capital now holds 1.23%

Post 1 updated

[please check for typos/calculation errors. It's easy to lose a decimal point]

[bamboo2] 30/9/2024 20:30

Oxford Nanopore Technologies and UMC Utrecht collaborate on 1,000 human genome sequencing project



The nanopore sequencing pilot programme aims to expand our understanding of the causes of rare genetic disease and cancer and evaluate potential for future routine clinical use.

Oxford Nanopore Technologies is entering into a strategic collaboration with UMC Utrecht, one of the leading academic medical centres in the Netherlands, that will aim to explore the genetic underpinnings of rare genetic disorders and certain cancers. The two-year initiative will sequence 1,000 human genomes, focusing on creating a single test capable of identifying all methylation, short tandem repeats (STRs), and structural variants (SVs). The project also seeks to demonstrate the benefits of transitioning from exome sequencing to whole genome sequencing (WGS), which will provide richer and more comprehensive genetic data.

'This collaboration with UMC Utrecht exemplifies our determination to push the boundaries of genomic research', said Magali Kemoun, Director of Sales EMEAI South at Oxford Nanopore. 'By integrating our advanced PromethION platform, we aim to not only enhance the capabilities of UMC Utrecht’s research but also contribute valuable data to the global scientific community. The insights gained from this project could pave the way for significant advancements in human genetics and disease research'.

UMC Utrecht’s clinical genetic lab, already a hub for extensive genetic testing, will utilise the PromethION 24 to reduce the number of tests and technologies currently in use - a battery of tests that can be as numerous as 15 in total - focusing on the strengths of nanopore sequencing. The pilot project aims to compare traditional short-read sequencing with Oxford Nanopore’s any-length read sequencing, demonstrating the added value of richer data, particularly in the identification of SVs, methylation patterns, and STRs. Additionally, the project will work towards automating sample preparation to support the hospital’s large throughput needs.

Marcel Nelen, Head Genome Diagnostics Section at UMC Utrecht, said: 'This collaboration will allow us to pursue innovative avenues in clinical genetic testing. A generic long read sequencing workflow as the engine of our genome diagnostics section will greatly help us cope with the growing demand for genetic diagnostics. By reducing the number of tests required to provide answers to the clinical questions asked, we can make a big efficiency gain'.

The project’s outcomes are anticipated to showcase the benefits of comprehensive whole genome sequencing over legacy methods, while demonstrating Oxford Nanopore’s potential in reducing the complexity and cost of utilising multiomic insights in hospital settings.

[steeplejack] 30/9/2024 15:27

Puretech is lowest market cap constituent of the FTSE250 by a large margin at £369m,PZ Cussons has a mkt cap of 418m and essentra has a cap of £441.I think we’ve got another 2 or 3 in the £400m bracket but.therafter all constituents have a market cap of over £500m.Fidelity Emerging is a tad over £500m,Austin Technology at £512m..If you’re up around 325th in the ratings you’ll be promoted to the FT250 which relates to a market cap currently of comfortably over £500m.Some 25 plus constituents currently have a market cap under £600m

[shared24] 30/9/2024 14:32

That's great, thanks bamboo.

[bamboo2] 30/9/2024 11:31

FT250 highest mcap BLND £4132m
FT250 lowest mcap PRTC £369m

ONT mcap £1546m

ONT should find a place about mid-table.

[shared24] 30/9/2024 10:49

Thanks Brucie for sharing your thoughts. I hope everything aligns for the expected share price growth and everyone is rewarded for their patience.

Is there a share price limit ONT should hit after next week for FTSE 250 inclusion? Or does it have the market cap already for it to be considered next week after the takeover protection ends?

[brucie5] 30/9/2024 09:21

Shared, I'm not the expert on this board and there are so many moving parts. But my feeling is that so long as they manage to maintain the growth in revenues towards 2027 and there is no disruption to the unfolding story, the share price will simply continue to progress back in the direction that it has fallen until it's taken out. £2 is the immediate hurdle; thereafter, it might spend some time ranging around the zone of £2-3, bearing in mind that it spent 18 months there on the way down. So you might need to be patient for that £6.90, though revenue growth at 30% with improving margins might be expected to have a compounding effect on the share price, no?

[shared24] 29/9/2024 20:48

Hi,Thanks for all the discussions and info. I have found it very useful.I bought into this about 3 years ago at 690 and have held it ever since.I strongly believe in the tech and the company. Is there any hope of the share price ever reaching 600 again?

[brucie5] 27/9/2024 13:36

I guess it's now safe to say we've broken out again. If Cwr can surge 20% in a day, then entanglement suggests, so might this.
😉

[ih_828197] 27/9/2024 12:28

i've been looking at CWR and the story seems very compelling but most of my capital is locked in ONT and i don't want to sell :/ so i'll probably start adding as paychecks came in as long as it doesn't fly away ahahah

[brucie5] 27/9/2024 11:23

Delighted that you're back to B/E on your core holding. I'm holding out to >£2 before I reconsider, though my convictions about specific opportunities are always severely tested by what then suddenly appears with others. Item: CWR, where i have been temporarily absent, up rather sharply today. I have suspected for some time the two of them are somehow entangled at the quantum level, such is the similarity of their chart stories.
;)

[apple53] 27/9/2024 11:01

So indeed Brucie back over my breakeven, but really no idea near term, beyond what I wrote earlier about possible resistance between 160 and 170.
I did sell that small chunk into the spike on the 19th, bought back on the dip, and sold the same into the spike this morning. Of course I had no idea if it was a spike or the beginning of the run towards £2. It seems wrong to be paying stamp, but I guess it's designed in part to stop people flipping (!). Does it also reduce liquidity......? Normally I would require at least a 10x gain vs a combination of spread and stamp (and the ii fee), but I have been making an exception recently.

Charts are useful but also dangerous. You can see the £3-6 area as easily obtainable, and so keep buying all the way down (which I basically did, with a little trading), but I also remember buying at 89p in June (and selling the same with gusto below 110p - my glass is half full). And with valuation nigh-on impossible I don't have a fundamental target.

One would have thought the takeover protection removal should now be priced in. I don't know about index inclusion however. If I am disciplined, if we get over 170, I hope I can resist selling any more until much closer to 200p. If we start flying, professionals would talk about using a trailing stop, but boy is this hard to apply.

[brucie5] 27/9/2024 08:48

Ha ha.
We seem to be on a tear this morning early doors, but it never pays to get excited. It could yet be down on the day.

[steeplejack] 27/9/2024 08:31

Never fear.... "We are all in the gutter, but some of us are looking at the stars."

[stallone10] 27/9/2024 08:09

Illuminati worth 20 billion us.
Could this be a NVADIA.

[brucie5] 26/9/2024 16:57

I seem to remember Oscar Widlde's definition of a cynic: someone who knows the price of everything and the value of nothing. I hope holders don't become cynics in selling this long short of true value for some short term gain.

[the big fella] 26/9/2024 15:44

Everything has a price.

[brucie5] 26/9/2024 14:56

Can't help with your question but looking forward to seeing what the next fortnight brings...
Thanks for continued work both here and on IPO.
PS. I sincerely hope noone gets a bid in, though they might try. I suspect pre-interested holders might not be too happy.

[bamboo2] 26/9/2024 14:49

Brucie, maybe Featurespace combined with less than seven trading days to go until ONT becomes biddable.

Anyone know when this will become legible for inclusion in the indices?
This will open up the share to trackers and many trust fund/investment funds.